Announcements
- CytoSorbents to Report First Quarter 2024 Operating and Financial Results
- STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
- CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
- CytoSorbents to Report Fiscal 2023 Operating and Financial Results
- CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference
- Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients
- CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation
- CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering
- CytoSorbents Reports Third Quarter 2023 Financial and Operational Results
- CytoSorbents to Report Third Quarter 2023 Operating and Financial Results
More ▼
Key statistics
On Friday, Cytosorbents Corp (HQE1:DUS) closed at 0.741, 4.22% above its 52-week low of 0.711, set on Apr 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.725 |
---|---|
High | 0.743 |
Low | 0.721 |
Bid | 0.738 |
Offer | 0.777 |
Previous close | 0.754 |
Average volume | 1.09k |
---|---|
Shares outstanding | 54.31m |
Free float | 49.21m |
P/E (TTM) | -- |
Market cap | 44.48m USD |
EPS (TTM) | -0.6375 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 18:31 BST.
More ▼